Gufic Biosciences Limited

Gufic Biosciences Limited

Gufic Biosciences Limited has informed the Exchange regarding Proceedings of 42nd Annual General Meeting held on September 04, 2026

Gufic Biosciences Limited

Gufic Biosciences Limited has informed the Exchange about the promotion and change in designation of two senior management personnel, Ms. Ami Shah as Head-Legal and Mr. Pinak Padhya as President – Sales & Marketing, effective September 02, 2026.

Gufic Biosciences Limited

Gufic Biosciences Limited has informed the Exchange about the written transcript of the Earnings Conference Call held on August 17, 2026, for Q1 FY27.

Gufic Biosciences Limited

Gufic Biosciences Limited has informed the Exchange about a Special Window for Re-lodgement of Transfer and Dematerialization of Physical Shares, as per SEBI Circular No. HO/38/13/11(2)2026-MIRSD-POD/I/3750/2026.

Gufic Biosciences Limited

Gufic Biosciences Limited has uploaded the audio recording of its earnings conference call on its website, as per Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Gufic Biosciences Limited

Gufic Biosciences Limited has published unaudited financial results for the quarter ended June 30, 2026, in accordance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Gufic Biosciences Limited

Gufic Biosciences Limited has submitted its Investor Presentation for Q1FY2027, highlighting its advanced lyophilized injectable facility, production milestones, and future plans for capacity expansion and product launches.

Gufic Biosciences Limited

Gufic Biosciences Limited has informed the Exchange about the approval of the incorporation of a subsidiary in the Philippines and investment by way of subscription to its equity share capital.

Gufic Biosciences Limited

Gufic Biosciences Limited has submitted its unaudited financial results for the quarter ended June 30, 2026, along with the approval of incorporating a subsidiary in the Philippines and investing in its equity share capital. The company has also disclosed its unaudited financial results, which show a revenue of ₹26,122.75 lakhs and an expense of ₹10,611.42 lakhs.

Gufic Biosciences Limited

Gufic Biosciences Limited has informed the Exchange about Copy of Newspaper Publication of Notice of 42nd Annual General Meeting of the Company and e-voting details.

Gufic Biosciences Limited

Gufic Biosciences Limited has announced the record date for its 42nd Annual General Meeting (AGM) and dividend payment. The record date is August 28, 2026, and the AGM will be held on September 4, 2026. The company will close its register of members and share transfer books from August 29 to September 4, 2026, for the purpose of the AGM and dividend payment.

Gufic Biosciences Limited

Gufic Biosciences Limited has informed the Exchange regarding Notice of 42nd Annual General Meeting to be held on September 04, 2026, with the Register of Members and Share Transfer Books closed from August 29, 2026 to September 04, 2026 for the purpose of AGM and payment of final dividend.

Gufic Biosciences Limited

Gufic Biosciences Limited has informed the Exchange about a copy of newspaper publication regarding the 42nd Annual General Meeting of the Company, scheduled to be held on September 04, 2026, through Video Conferencing / Other Audio Visual Means (VC/OAVM). The Company has also mentioned a commercial dispute under section 6 of the Commercial Courts Act, 2013, related to a lawsuit filed by Bank of India against the Company.

Gufic Biosciences Limited

Gufic Biosciences Limited has informed the Exchange regarding the re-appointment of Mr. Pankaj J Gandhi as Whole Time Director of the company, effective September 07, 2026.

Gufic Biosciences Limited

Gufic Biosciences Limited has informed the Exchange regarding the outcome of its Board Meeting held on July 31, 2026, where the Board has re-appointed Mr. Pankaj Jayakumar Gandhi as the Whole Time Director of the Company for a further term of 5 years.

Gufic Biosciences Limited

Gufic Biosciences Limited has submitted a certificate under SEBI (Depositories and Participants) Regulations, 2018, confirming the dematerialization of securities for the quarter ended June 30, 2026.

Gufic Biosciences Limited

Gufic Biosciences Limited has informed the Exchange about a copy of a newspaper publication regarding the transfer of equity shares to the Investor Education and Protection Fund (IEPF) Authority.

Gufic Biosciences Limited

Gufic Biosciences Limited has submitted a disclosure under SEBI Takeover Regulations, as per Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, filed by Jayesh P. Choksi.

Gufic Biosciences Limited

Gufic Biosciences Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015. The Trading Window for dealing in securities of the Company shall remain closed for all the Designated Persons and their immediate relatives from Wednesday, July 01, 2026 till 48 hours after the declaration of Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter ended June 30, 2026.

Gufic Biosciences Limited

Gufic Biosciences Limited has informed the Exchange about a Special Window for Re-lodgement of Transfer and Dematerialization of Physical Shares, as per SEBI Circular No. HO/38/13/11(2)2026-MIRSD-POD/I/3750/2026 dated January 30, 2026.